20mins delayed


1 Year Return

System message

BIG CHANGES! Try the new Market Index

For the best experience, create a free account.

Hexima Ltd Chart

Share price
Market Cap $19.86 million
Today's Movement
Prev. Close
Day Range -
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover

HXL Statistics

15 January

1,764 / 2,260

ASX Size Rank

1yr Return

vs Sector (1yr)


vs ASX 200 (1yr)


$19.86 million

Market Cap

Share Issue

120.37 million

All Ords (%)


Short Sold


Current Fundamentals

15 January


PE Ratio

EPS ($)


Earnings Yield


NTA ($)



Dividend Yield

DPS ($)


Gross Div. Yield


Gross DPS ($)


Company Overview

Hexima Limited (HXL) is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis.

Hexima Ltd Logo

Corporate Details

Head Office: Melbourne
Managing Director: Michael Aldridge
GICS Sub-Industry: Biotechnology
Date Listed: 1 Dec 2020
Registry: -
Similar Companies: CSL / MSB / CUV / OPT / AVH

Upcoming Calendar

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.


Date Heading Pages File Size Time

Announcements provided by

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

HXL is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.

Directors & Management

About the Data

Name Title Since Bio
Mr Steven Michael Skala Alternate Director Mar 2020
Mr Michael Douglas Aldridge Chief Executive Officer, Managing Director May 2019
Professor Jonathan Paul West Non-Executive Director, Non-Executive Chairman Nov 2005
Mr Scott Christian Robertson Non-Executive Director Nov 2018
Professor Marilyn Ann Anderson Chief Science Officer, Executive Director Nov 2010
Dr Nicole Louise van der Weerden Chief Operating Officer, Executive Director Dec 2014
Mr Justin Zhen Nan Yap Non-Executive Director Jul 2018
Marilyn A Anderson Chief Science Officer N/A
Helen Molloy Company Secretary, Finance Controller N/A
Robyn L Heath Senior Vice President Product Development N/A

Director Transactions

About the Data

HXL directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

There are no director transactions for code HXL in our database.

Shareholder Distribution

Shareholder Distribution data is unavailable.

Top 20 Shareholders

About the Data

Name Shares Capital
Dato Lim Sen Yap 14,715,790 11.25%
Caroline House Superannuation Fund Pty Ltd (Caroline House S/F A/C) 8,287,131 6.33%
Woobinda Nominees Pty Ltd (The Woobinda Family A/C) 6,372,222 4.87%
Beta Gamma Pty Ltd (Walsh Street Super Fund A/C) 5,736,586 4.38%
Gowing Bros Limited 4,256,176 3.25%
Paul Orlin 3,750,000 2.87%
Gowing Bros Ltd 3,667,131 2.80%
HSBC Custody Nominees (Australia) Limited 3,496,219 2.67%
Balmoral Financial Investments Pty Ltd 3,051,090 2.33%
Adrienne Clarke 3,028,938 2.31%
Hugh Morgan 2,977,252 2.28%
Dalit Pty Ltd (Dalit Family A/C) 2,500,000 1.91%
Dongrisha Pty Ltd (The Dongrisha Investment A/C) 2,500,000 1.91%
Huysmans Pty Ltd (The Lama A/C) 2,346,011 1.79%
Marilyn Anderson 2,280,548 1.74%
Saxum Pty Ltd 2,106,755 1.61%
Cranley Nominees Pty Ltd (Fitzroy Family A/C) 2,007,674 1.53%
Pioneer Hi-Bred International Inc. 2,000,000 1.53%
Andama Holdings Pty Ltd (J & M Barlow Pension A/C) 1,851,057 1.41%
Mr Leon Francis Lachal & Mrs Susan Margaret Lachal (The Lachal Super Fund A/C) 1,779,249 1.36%
All other shareholders 39.87 %

The Top 20 Shareholders of HXL hold 60.13% of shares on issue.

HXL Share Price History

Date Close Change % Change Open High Low Volume Turnover

HXL Historical Data

Download up to 20 years of share price history.

Year Closing Price (30 June) Last Trade

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Research and development of plant-derived proteins and peptides for applications as human therapeutics.

Incorporated: --

Level 4, LIMS2, Plenty Rd
Melbourne VIC 3086

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.